global apex knee system tibial baseplate non-porous cemented - uncoated knee tibia prosthesis, metallic
global orthopaedic technology pty ltd -
global apex knee system ps-r insert - prosthesis, knee, internal, insert component
global orthopaedic technology pty ltd -
global apex knee system modular tibial baseplate, cemented - uncoated knee tibia prosthesis, metallic
global orthopaedic technology pty ltd -
global apex knee system, revision femur, ps, cemented - uncoated knee femur prosthesis
global orthopaedic technology pty ltd -
topiramate teva 300 mg
teva pharmaceutical industries ltd, israel - topiramate - tablets - topiramate 300 mg - topiramate - topiramate - topiramate teva is indicated as adjunctive therapy for adults and children from 2 years and above with partial onset seizures or generalized tonic-clonic seizures. topiramate teva is also indicated in adults and children as adjunctive therapy for the treatment of seizures associated with lennox-gastaut syndrome . topiramate teva is indicated as monotherapy in patients with newly diagnosed epilepsy in adults and children aged 7 years and above or for conversion to monotherapy in patients with epilepsy.topiramate teva is indicated in adults for the prevention of migraines. the use of topiramate teva in the acute treatment of migraine has not been studied .
topiramate teva 300 mg
teva pharmaceutical industries ltd, israel - topiramate - tablets - topiramate 300 mg - topiramate - topiramate - topiramate teva is indicated as adjunctive therapy for adults and children aged 6 and above with partial onset seizures or generalized tonic-clonic seizures. topiramate teva is also indicated in adults and children as adjunctive therapy for the treatment of seizures associated with lennox-gastaut syndrome . topiramate teva is indicated as monotherapy in patients with newly diagnosed epilepsy in adults and children aged 7 years and above or for conversion to monotherapy in patients with epilepsy.
topiramate teva 400 mg
teva pharmaceutical industries ltd, israel - topiramate - tablets - topiramate 400 mg - topiramate - topiramate - topiramate teva is indicated as adjunctive therapy for adults and children from 2 years and above with partial onset seizures or generalized tonic-clonic seizures. topiramate teva is also indicated in adults and children as adjunctive therapy for the treatment of seizures associated with lennox-gastaut syndrome . topiramate teva is indicated as monotherapy in patients with newly diagnosed epilepsy in adults and children aged 7 years and above or for conversion to monotherapy in patients with epilepsy.topiramate teva is indicated in adults for the prevention of migraines. the use of topiramate teva in the acute treatment of migraine has not been studied .
topiramate teva 400 mg
teva pharmaceutical industries ltd, israel - topiramate - tablets - topiramate 400 mg - topiramate - topiramate - topiramate teva is indicated as adjunctive therapy for adults and children aged 6 and above with partial onset seizures or generalized tonic-clonic seizures. topiramate teva is also indicated in adults and children as adjunctive therapy for the treatment of seizures associated with lennox-gastaut syndrome . topiramate teva is indicated as monotherapy in patients with newly diagnosed epilepsy in adults and children aged 7 years and above or for conversion to monotherapy in patients with epilepsy.
diltiazem teva 30 mg
teva israel ltd - diltiazem hydrochloride - tablets - diltiazem hydrochloride 30 mg - diltiazem - diltiazem - calcium channel blocker for the treatment of angina pectoris.
pravastatin teva 10 mg
teva pharmaceutical industries ltd, israel - pravastatin sodium - tablets - pravastatin sodium 10 mg - pravastatin - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute c